AM
Publicaties op Oncologisch.com
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monothera...
Atezolizumab plus cabozantinib versus docetaxel bij gemetastaseerd NSCLC: CONTACT-01 fase III
Atezolizumab plus cabozantinib versus cabozantinib alleen bij mRCC: CONTACT-03 fase III